Complex medicines for correction of urine pH level during urolithiasis metaphylaxis

Introduction. Urolithiasis is a serious medical, social and economic problem. Over the past decades the world has seen a progressive, approximately 3% per year, increase in its incidence. Urolithiasis occupies a leading position in the structure of urological diseases and has a high recurrence rate in the absence of metaphylaxis. In turn, the effectiveness of properly selected anti-relapse therapy has been proven by many studies and is about 5080%. The development of “tools” for rational metaphylaxis represents a potential “growth area” for improving the effectiveness of treatment for patients with urolithiasis. One of these tools is the correction of urine pH levels, since its violations are the most common. However, drugs used to correct pH levels have a number of limitations, which greatly complicates their use. One of the possible solutions to these shortcomings may be the creation of combined drugs that can comprehensively influence the factors that provoke the recurrence of stone formation such as the line of Lit-control® Litura® products from Devicare (Spain). The purpose of this publication is the scientific rationale of the clinical effects of Litura® Up and Litura® Down in the metaphylaxis of urolithiasis.